Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects

Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects

Bibliographic Details
Main Authors:	Haahr, Hanne, Sasaki, Tomio, Bardtrum, Lars, Ikushima, Ippei
Format:	Online
Language:	English
Published:	John Wiley and Sons Inc. 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931208/

Similar Items

Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients
by: Ikushima, Ippei, et al.
Published: (2015)

Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus
by: Heise, Tim, et al.
Published: (2014)

A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
by: Haahr, Hanne, et al.
Published: (2014)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
by: Nasrallah, Sami N., et al.
Published: (2012)

Degludec insulin: A novel basal insulin
by: Kalra, Sanjay, et al.
Published: (2011)

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
by: Kalra, Sanjay
Published: (2016)

Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region
by: Nosek, Leszek, et al.
Published: (2014)

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
by: Kalra, Sanjay
Published: (2014)

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment
by: Kupčová, Viera, et al.
Published: (2013)

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment
by: Kiss, István, et al.
Published: (2013)

Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart
by: Havelund, Svend, et al.
Published: (2015)

Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co‐formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial
by: Rodbard, H. W., et al.
Published: (2016)

Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
by: Kalra, Sanjay
Published: (2013)

Effect of switching basal insulin regimen to degludec on quality of life in Japanese patients with type 1 and type 2 diabetes mellitus
by: Okada, Morihiro, et al.
Published: (2015)

Insulin degludec aspart: One-year real world experience
by: Kalra, Sanjay, et al.
Published: (2016)

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
by: Niskanen, Leo, et al.
Published: (2012)

Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective
by: Evans, Marc, et al.
Published: (2016)

The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes
by: Brunner, Martina, et al.
Published: (2015)

Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes
by: Thalange, Nandu, et al.
Published: (2015)

Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement
by: Kalra, Sanjay, et al.
Published: (2016)

Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes
by: Dardano, Angela, et al.
Published: (2014)

Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study
by: Koehler, Gerd, et al.
Published: (2013)

In-hospital experience with insulin degludec (IDeg)
by: Bulisani, Maria Gabriela Pedigoni, et al.
Published: (2015)

Pediatric diabetes: Potential for insulin degludec
by: Kalra, Sanjay, et al.
Published: (2014)

Twice‐daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin‐naïve adults with Type 2 diabetes
by: Franek, E., et al.
Published: (2015)

Meta-analysis of insulin aspart versus regular human insulin used in a basal–bolus regimen for the treatment of diabetes mellitus
by: Heller, Simon, et al.
Published: (2013)

Towards a Physiological Prandial Insulin Profile: Enhancement of Subcutaneously Injected Prandial Insulin Using Local Warming Devices
by: El-Laboudi, Ahmed H., et al.
Published: (2015)

Faster‐acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart
by: Heise, T., et al.
Published: (2015)

Medium-Term Effects of Insulin Degludec on Patients with Type 1 Diabetes Mellitus
by: Nakae, Rie, et al.
Published: (2014)

Efficacy and safety of insulin degludec given as part of basal–bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial
by: Davies, M J, et al.
Published: (2014)

Switching from Twice-Daily Basal Insulin Injections to Once-Daily Insulin Degludec Injection for Basal-Bolus Insulin Regimen in Japanese Patients with Type 1 Diabetes: A Pilot Study
by: Tosaka, Yuka, et al.
Published: (2015)

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
by: Wang, Fei, et al.
Published: (2012)

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
by: Jonassen, Ib, et al.
Published: (2012)

In search of the ideal basal insulin: Does the new‐generation ultra‐long‐acting insulin, degludec, provide the answer?
by: Hui, Elaine, et al.
Published: (2013)

Ultra-Long Pharmacokinetic Properties of Insulin Degludec are Comparable in Elderly Subjects and Younger Adults with Type 1 Diabetes Mellitus
by: Korsatko, S., et al.
Published: (2013)

Insulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial
by: Iwamoto, Yasuhiko, et al.
Published: (2013)

Short Report: Treatment Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal–Bolus Type 1): 2-year results of a randomized clinical trial
by: Bode, B W, et al.
Published: (2013)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
by: Kusunoki, Yoshiki, et al.
Published: (2013)

Patient safety and minimizing risk with insulin administration – role of insulin degludec
by: Aye, Myint M, et al.
Published: (2014)

Degludec: the new ultra-long insulin analogue
by: Tambascia, Marcos Antonio, et al.
Published: (2015)